» Articles » PMID: 24606434

Improved Long-term Survival with Contralateral Prophylactic Mastectomy Among Young Women

Overview
Specialty Oncology
Date 2014 Mar 11
PMID 24606434
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Despite mixed survival data, the utilization of contralateral prophylactic mastectomy (CPM) for the prevention of a contralateral breast cancer (CBC) has increased significantly over the last 15 years, especially among women less than 40. We set out to look at our own experience with CPM, focusing on outcomes in women less than 40, the sub-population with the highest cumulative lifetime risk of developing CBC. With an extended follow-up, we hoped to demonstrate differences in the long-term disease free survival (DFS) and overall survival (OS) among groups who underwent the procedure (CPM) versus those that did not (NCPM).

Materials And Methods: We performed a retrospective review of all breast cancer patients less than age 40 diagnosed at Mount Sinai Medical Center between January 1, 1980 and December 31, 2010 (n=481). Among these patients, 42 were identified as having undergone CPM, while 195 were confirmed as being CPM-free during the observation period. A univariate and multivariate analyses were performed.

Results: The CPM group had a significantly higher percentage of patients who were diagnosed between 2000 and 2010 (95.2% vs 40%, p=0.0001). The CPM group had significantly smaller tumors (0-2cm.: 41.7% vs 24.8%, p=0.04). Among the entire group of patients, the overall five- and 10-year DFS were 81.3% and 73.3%, respectively. CPM was significantly associated [HR 2.35 (1.02, 5.41); p=0.046] with 10-year OS, although a similar effect was not observed for five-year OS.

Conclusions: We found that CPM has increased dramatically over the last 15 years, especially among white women with locally advanced disease. In patients less than 40, who are thought to be at greatest cumulative risk of secondary breast cancer, CPM provided an OS advantage, regardless of genetics, tumor or patient characteristics, and which was only seen after 10 years of follow-up.

Citing Articles

Survival Outcomes in Women with Unilateral, Triple-Negative, Breast Cancer Correlated with Contralateral Prophylactic Mastectomy.

Fasano G, Bayard S, Chen Y, Marti J, Simmons R, Swistel A Ann Surg Oncol. 2023; 30(8):4648-4656.

PMID: 36681737 DOI: 10.1245/s10434-022-13056-0.


Current Considerations in Surgical Treatment for Adolescents and Young Women with Breast Cancer.

Murphy B, Pereslucha A, Boughey J Healthcare (Basel). 2022; 10(12).

PMID: 36554065 PMC: 9777860. DOI: 10.3390/healthcare10122542.


Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes.

Peleg Hasson S, Menes T, Sonnenblick A Pharmgenomics Pers Med. 2020; 13:227-238.

PMID: 32801835 PMC: 7394592. DOI: 10.2147/PGPM.S233485.


Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer Who Are Genetic Carriers, Have a Strong Family History or Are just Young at Presentation.

Teoh V, Tasoulis M, Gui G Cancers (Basel). 2020; 12(1).

PMID: 31935898 PMC: 7016894. DOI: 10.3390/cancers12010140.


Genetic ablation of mammary ducts through foxa1 prevents breast cancer occurrence.

Zheng D, McLaughlin S, Kaestner K, Li Z Am J Cancer Res. 2019; 9(2):424-428.

PMID: 30906639 PMC: 6405962.